Eligibility check
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Step 1 of 5
Where are you located?
We confirm your state so we only show studies you can actually reach.
Your answers help match you to studies and connect you with the research team. They're handled per our Privacy Policy.